[1]蔡怀阳,李运泽,邹劲涛,等.血浆内脏脂肪素与非酒精性脂肪性肝病患者胰岛素抵抗的关系[J].医学信息,2021,34(09):128-130.[doi:10.3969/j.issn.1006-1959.2021.09.034]
　CAI Huai-yang,LI Yun-ze,ZOU Jin-tao,et al.The Relationship Between Plasma Visceral Fat and Insulin Resistance in Patients with Non-alcoholic Fatty Liver Disease[J].Medical Information,2021,34(09):128-130.[doi:10.3969/j.issn.1006-1959.2021.09.034]
点击复制

血浆内脏脂肪素与非酒精性脂肪性肝病患者胰岛素抵抗的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年09期
页码:
128-130
栏目:
临床研究
出版日期:
2021-05-01

文章信息/Info

Title:
The Relationship Between Plasma Visceral Fat and Insulin Resistance in Patients with Non-alcoholic Fatty Liver Disease
文章编号:
1006-1959（2021）09-0128-03
作者:
蔡怀阳; 李运泽; 邹劲涛; 等
（柳州市人民医院消化内科1，核医学科2，体检部3，广西 柳州 545006）
Author(s):
CAI Huai-yang; LI Yun-ze; ZOU Jin-tao; et al.
(Department of Gastroenterology1,Department of Nuclear Medicine2,Department of Physical Examination3, Liuzhou People’s Hospital,Liuzhou 545006,Guangxi,China)
关键词:
非酒精性脂肪性肝病; 内脏脂肪素; 胰岛素抵抗
Keywords:
Non-alcoholic fatty liver disease; Visceral fat; Insulin resistance
分类号:
R575.5
DOI:
10.3969/j.issn.1006-1959.2021.09.034
文献标志码:
A
摘要:
目的 探讨血浆内脏脂肪素与非酒精性脂肪性肝病（NAFLD）患者胰岛素抵抗的关系。方法 选取2013年7月~2014年12月于柳州市人民医院非酒精性脂肪性肝病患者110例，根据严重程度分为轻度NAFLD组（40例）、中度NAFLD组（40例）和重度NAFLD组（30例），另外选取同期体检正常者作为对照组（60例）。比较各组身高、体质量、臀围、腰围、甘油三脂、总胆固醇、血糖、肝功能、胰岛素水平、血浆内脏脂肪素水平及胰岛素抵抗（HOMA-IR）情况。结果 各组体质量、体质量指数、腰臀比、内脏脂肪素及HOMA-IR比较，差异有统计学意义（P＜0.05）；轻度NAFLD组、中度NAFLD组、重度NAFLD组内脏脂肪素依次升高，差异有统计学意义（P＜0.05）；轻度NAFLD组、中度NAFLD组、重度NAFLD组HOMA-IR比较，差异有统计学意义（P＜0.05）；相关性分析显示，血浆内脏脂肪素水平与HOMA-IR呈正相关；轻度NAFLD组、中度NAFLD组、重度NAFLD组中，内脏脂肪素与HOMA-IR的相关性依次增强（r=0.253、0.508、0.650）。结论 非酒精性脂肪性肝病患者血浆内脏脂肪素水平及HOMA-IR高于健康人群，其与胰岛素抵抗存在一定的关系。
Abstract:
Objective To investigate the relationship between plasma and insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD).Methods A total of 110 patients with non-alcoholic fatty liver disease in Liuzhou People’s Hospital from July 2013 to December 2014 were selected.According to the severity, they were divided into mild NAFLD group (40 cases), moderate NAFLD group (40 cases) and severe NAFLD group (30 cases).In addition, people with normal physical examination during the same period were selected as the control group (60 cases).Compare the height, body weight, hip circumference, waist circumference, triglycerides, total cholesterol, blood sugar, liver function, insulin level, plasma visceral fat level and insulin resistance (HOMA-IR) in each group.Results There were statistically significant differences in body mass, body mass index, waist-to-hip ratio, visceral fat and HOMA-IR in each group (P<0.05);Visceral fats in the mild NAFLD group, moderate NAFLD group, and severe NAFLD group increased sequentially,the difference was statistically significant (P<0.05);Comparison of HOMA-IR between mild NAFLD group, moderate NAFLD group, and severe NAFLD group, the difference was statistically significant (P<0.05);Correlation analysis showed that plasma visceral levels were positively correlated with HOMA-IR; in the mild NAFLD group, moderate NAFLD group, and severe NAFLD group, the correlation between visceral fat and HOMA-IR increased in turn (r=0.253, 0.508 ,0.650).Conclusion The levels of plasma visceral fat and HOMA-IR in patients with non-alcoholic fatty liver disease are higher than those in healthy people, and there is a certain relationship between them and insulin resistance.

参考文献/References:

[1]Perla FM,Prelati M,Lavorato M,et al.The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease[J].Children(Basel),2017,4(6):E46. [2]Kitade H,Chen G,Ni Y,et al.Nonalcoholic fatty liver disease and insulin resistance:new insights and potential new treatments[J].Nutrients,2017,9(4):E387. [3]医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J].中华肝病杂志,2010,18(3):163-166 [4]Li YH,Zhu HJ.Study OU efkct of oral Chinese medicine compared with polyene hosphatidylcholine group treatment for non-alcoholic’,fatty liver disease[J].Practical Pharmacy and Clinical Remedies,2014,17(8):1016-1018． [5]Hu YY.Advantages and prospects of traditional Chinese medicine in treating nonalcoholic fatty liver disease[J].World Chinese Medicine,2015,10(2):149. [6]McPherson S,Hardy T,Henderson E,et al.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management[J].J Hepatol,2015,62(5):1148-1155. [7]NCD Risk Factor Collaboration(NCD-RisC).Trends in adult bodymass index in 200 countries from 1975 to 2014:a pooled analysis of 1698 population based measurement studies with 192 million participants[J].Lancet,2016,387(10026):1377-1396. [8]Dongiovanni P,Valenti L.A nutrigenomic approach to non-alcoholic fatty liver disease[J].Int J Mol Sci,2017,18(7):pii:E1534. [9]Petit JM,Vergès B.GLP-1 receptor agonists in NAFLD[J].Diabetes Metab,2017,43(Suppl1):2S28-2S33. [10]范小芬,邓银泉,吴国琳.非酒精性脂肪性肝病患者血清 TNF-α、IL-6 水平与胰岛素抵抗相关性研究[J].现代中西医结合杂志,2015,24(33):3683-3684. [11]申甜,徐碧林,盛霞,等非酒精性脂肪肝大鼠肝组织FGF21mRNA表达与脂质沉积、胰岛素抵抗的关系[J].山东医药,2016,56(8):9-12.

相似文献/References:

[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
　LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(09):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]崔姗姗,刘 英,江 霞.非酒精性脂肪性肝病与胰岛素抵抗的研究进展[J].医学信息,2022,35(10):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
　CUI Shan-shan,LIU Ying,JIANG Xia.Research Progress on Non-alcoholic Fatty Liver Disease and Insulin Resistance[J].Medical Information,2022,35(09):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
[3]冯贺强,张彩红.肠道菌群与非酒精性脂肪肝关系的研究进展[J].医学信息,2018,31(12):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
　FENG He-qiang,ZHANG Cai-hong.Research Progress on the Relationship between Intestinal Flora and Nonalcoholic Fatty Liver[J].Medical Information,2018,31(09):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
[4]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
　ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Medical Information,2018,31(09):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[5]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
　LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(09):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[6]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
　HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in A Certain Area of Tianjin[J].Medical Information,2019,32(09):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[7]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
　YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2019,32(09):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
[8]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病 中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
　WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with Nonalcoholic Fatty Liver Disease[J].Medical Information,2019,32(09):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
[9]蒋晓倩,梁惠卿,刘垚昱,等.吴耀南运用“浊毒”理论论治非酒精性脂肪性肝病验案举隅[J].医学信息,2020,33(04):158.[doi:10.3969/j.issn.1006-1959.2020.04.052]
[10]蔡秀媛,吴春城,梁惠卿,等.非酒精性脂肪性肝病中医证型与客观指标的相关性[J].医学信息,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
　CAI Xiu-yuan,WU Chun-cheng,LIANG Hui-qing,et al.Correlation Between TCM Syndromes of Nonalcoholic Fatty Liver Disease and Objective Indexes[J].Medical Information,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]

更新日期/Last Update: 1900-01-01